BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kereos, Inc. Increases Series B Financing Total To $20 Million


10/19/2005 5:13:23 PM

St. Louis, MO - October 14, 2005 - Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, has added a $500,000 investment from Advantage Capital Partners to its recently announced Series B Venture Financing, bringing the total raised to more than $20 million.

"We are pleased to welcome Advantage Capital to our outstanding syndicate of investors who have joined this round," said Robert A. Beardsley, Ph.D., President and CEO of Kereos. "As we advance into clinical trials in 2006, these investors stepping up now will be invaluable in developing our targeted products to tackle cancer and cardiovascular disease."

About Kereos, Inc.

Kereos develops products designed to provide more effective detection and treatment of cancer, the first two of which are expected to enter clinical trials for solid tumors in 2006. The company’s proprietary technology pairs diagnosis and therapy by targeting imaging agents or therapeutics specifically to the disease site. The company’s targeted imaging agents allow more accurate and sensitive imaging, and its targeted chemotherapeutics deliver potent and precise therapy. In addition to advancing its internal pipeline, Kereos is working with leading pharmaceutical and imaging companies, including Bristol-Myers Squibb Medical Imaging on the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and Philips Medical Systems on the development of molecular imaging systems. Kereos is headquartered in St. Louis at the Center for Emerging Technologies. For more information, visit Kereos’ website at www.kereos.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES